Hemab Therapeutics/X
Sep 2, 2025, 12:50
New COO at Hemab Therapeutics: Anant Murthy to Advance Rare Blood Disorder Treatments
Hemab Therapeutics posted on X:
”Hemab is growing fast, and we’re thrilled to announce our new Chief Operating Officer, Anant Murthy, PhD.
In this new role, Dr. Murthy will lead the company’s global efforts in market access, launch, and commercialization, bringing Hemab’s promising pipeline of treatments for Glanzmann thrombasthenia, Von Willebrand disease, and other neglected blood clotting disorders with high unmet needs to patients worldwide.
Read more here.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research